- Curaleaf has announced its intention to make an unsolicited offer for Aurora Cannabis but has not formally commenced the bid.
- Aurora won its hostile pursuit of CanniMed only after substantially increasing its offer and adding cash; Green Growth Brands’ hostile bid for Aphria failed.
- Aurora faces declining Canadian medical revenue, but CAD$149.1 million in cash, equivalents, and short-term investments with no debt give its board room to deliberate.
Curaleaf Holdings wants to buy Aurora Cannabis, and it intends to take the offer straight to Aurora’s shareholders. On August 11, the Stamford, Connecticut-based operator announced plans to launch an unsolicited bid for all of Aurora’s outstanding shares, offering 0.3463 Curaleaf shares plus US$0.75 in cash for each Aurora share. Curaleaf valued the proposed consideration at an implied US$4 per share, with the value capped at US$5 if Curaleaf’s stock climbs substantially before the shares are taken up. No formal bid has commenced.
Aurora tells a more complicated version of the story. In its own statement responding to Curaleaf’s announcement, Aurora confirmed receiving letters dated June 23 and July 7 but noted only the July 7 letter included financial terms. Aurora’s statement said the company’s lead independent director stayed in contact with Curaleaf’s CEO as recently as July 24, without shutting down further talks. Aurora’s board is forming a special committee of independent directors to review the proposal formally, rather than rejecting it outright.
It’s a familiar shape to anyone who has watched Canadian cannabis long enough to remember 2017. It’s also, more specifically, a shape Aurora itself designed.
Déjà vu, with the roles reversed
Aurora fired the starting gun on hostile cannabis takeovers in November 2017, when it made an unsolicited all-stock offer for Saskatchewan-based CanniMed Therapeutics. CanniMed’s board rejected the approach and deployed a poison pill to block Aurora from striking side deals with shareholders, then sued Aurora over the campaign. Aurora pressed ahead. In January 2018, it reached a supported agreement with CanniMed after increasing its offer substantially, adding a cash component, and valuing the transaction at approximately CAD$1.1 billion (then about US$852 million). The acquisition was completed later that year. At the time, it was the largest transaction in cannabis history and helped cement Aurora as one of the sector’s most closely watched licensed producers heading into legalization.
Eight years on, Aurora sits on the other end of that exact playbook: a private approach that didn’t produce an agreement, followed by a public appeal directly to shareholders. The broad shape of Curaleaf’s campaign resembles Aurora’s pursuit of CanniMed, although the proposed consideration and the target board’s opening response differ.
Cannabis takeover history offers two endings
Most reports about Curaleaf’s maneuver have treated the American giant’s hostile bid as a novelty, and understandably so. Genuinely “hostile” acquisitions are rare in a sector this small. But the move isn’t unprecedented, and the other major precedent complicates any tidy “history repeats itself” framing.
About a year after Aurora took CanniMed, Ohio-based Green Growth Brands launched its own hostile all-stock bid for Aphria, another major Canadian producer, initially valuing the target around CAD$2.8 billion. Aphria’s board rejected the offer outright in February 2019, arguing — per its own statement announcing the rejection — that the bid was a discount rather than a premium and would force a delisting from the Toronto Stock Exchange and New York Stock Exchange. Green Growth already had revised the offer down once by then, after its own stock price fell. The bid ultimately expired in April 2019 without meeting the statutory minimum tender condition, rather than simply fading away. Aphria remained independent for the rest of that year, before agreeing to a friendly merger with Tilray in 2020 on its own terms. Around the same time, Green Growth filed for insolvency protection in Canada.
Canadian cannabis has run this experiment twice already, with opposite results: Of the two conspicuous precedents, one succeeded only after the bidder sweetened its terms considerably; the other expired after too few shareholders tendered. In hindsight, the failure looks less like a fluke and more like an early tell about the bidder’s footing. That split record is worth keeping in mind before assuming Curaleaf’s bid for Aurora is destined to close just because Aurora once ran the winning side of the same play.
What Aurora’s share price signals
Curaleaf has framed Aurora’s board as having stonewalled two private overtures, in June and July. Aurora disputes that account, and the difference matters: CanniMed’s board rejected Aurora’s approach and deployed a poison pill almost immediately in 2017, a hard, combative opening move. Aurora’s board, so far, has done neither. It’s disputing Curaleaf’s characterization while setting up a formal review rather than a rejection. That’s a more measured opening posture than CanniMed’s, which makes the “Is this heading toward a CanniMed ending or an Aphria ending?” question genuinely open rather than a foregone conclusion.
The market’s early reaction reflects that uncertainty rather than settling it. Aurora’s Nasdaq-listed shares closed at US$3.48 after the dueling hostile-bid announcements, up about 20 percent from the previous close of US$2.89. The jump was striking for a stock that had been trading near its 52-week low. The closing price remained below Curaleaf’s stated implied value of US$4 per share. That spread does not predict the outcome by itself: Curaleaf has not formally launched the bid, most of the proposed consideration consists of fluctuating Curaleaf shares, and any transaction would face a lengthy process and closing risk. Still, the market plainly is not treating US$4 as money already in Aurora shareholders’ pockets.
Operating pressure without financial distress
Aurora’s own numbers complicate the question of whose position the timing favors. Its fiscal first-quarter 2027 results, reported August 5, showed net revenue of CAD$67.6 million, down 9 percent year over year. An approximately 30-percent reduction in Veterans Affairs Canada reimbursement rates hit Canadian medical revenue hard even as international medical sales grew 17 percent. Management has characterized fiscal 2027 as a transition year. Yet Aurora ended the quarter with CAD$149.1 million in cash, cash equivalents, and short-term investments and no debt. That balance sheet helps explain why Curaleaf emphasizes a much larger premium after subtracting Aurora’s cash from its valuation — but it also gives Aurora’s board room to deliberate. Curaleaf can point to near-term operating pressure; it cannot portray Aurora as a distressed seller forced to accept the offer.
A sequel worth watching, not assuming
None of this means Curaleaf’s bid will fail. Curaleaf plainly is motivated, and the terms it has announced say a formal bid would not include financing or due-diligence conditions. But Curaleaf has not commenced that bid and has reserved several grounds on which it could walk away before doing so. The first signal, therefore, will be whether Curaleaf files and mails the formal offer documents. The special committee’s subsequent recommendation will be the next real signal.
Aurora, of all companies, should understand exactly what its board is up against. It wrote an early version of this playbook itself.
